Wikisage, the free encyclopedia of the second generation, is digital heritage
Lamictal XR: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
mNo edit summary |
||
| Line 6: | Line 6: | ||
this presentation is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. | this presentation is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. | ||
==Links== | |||
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf | |||
<references/> | <references/> | ||
Revision as of 19:18, 15 April 2016
lamotrigine slow release[1] risk increases conmmitant administration with valproate
Stevens Johnson has been observed in 8 per 1000 cases
this presentation is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.